Small-cap cancer researcher GTx (NASDAQ: GTXI ) announced Tuesday that the U.S. Food and Drug Administration has granted "fast track" development status to its enobosarm (GTx-024) drug for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
Fast track status enables expedited development and regulatory review of test results for new drug candidates that target serious, currently untreated or insufficiently treated diseases. GTx said in a statement that the fast track designation gives it a greater chance of winning "priority review" for a New Drug Application for enobosarm. The company is currently conducting two phase III clinical trials of the drug, designated POWER 1 and POWER 2, testing its effects on patients suffering from stage III and IV non-small cell lung cancer.
The company says it expects to have top line data from these studies this summer.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.